Bendamustine

Generic Name: Bendamustine

Brand Names: Belrapzo, Bendeka, Treanda, Vivimusta

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₁Cl_₂N_₃O_₂

CAS Number: 16506-27-7

Unique Ingredient Identifier: 9266D9P3PQ

Background: Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.

Indication: Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions: Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma

Clinical Trials

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: FT825
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Bendamustine
Drug: Docetaxel
Drug: Cisplatin
Drug: Cetuximab

First Posted Date: 2024-02-05

Last Posted Date: 2024-12-24

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 351

Registration Number: NCT06241456

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
University of California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
Yale New Haven Hospital - Yale Cancer Center, New Haven, Connecticut, United States

and more 12 locations

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Phase 3

Withdrawn

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell

Interventions: Biological: Liso-cel
Drug: Idelalisib
Drug: Fludarabine
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Bendamustine

First Posted Date: 2024-01-16

Last Posted Date: 2024-04-02

Lead Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Registration Number: NCT06205290

Locations: 🇺🇸
Local Institution - 0068, Morgantown, West Virginia, United States
🇺🇸
Local Institution - 0121, New York, New York, United States
🇫🇷
Local Institution - 0036, Montpellier, Languedoc-Roussillon, France

and more 45 locations

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Phase 3

Recruiting

Conditions: Follicular Lymphoma (FL)

Interventions: Drug: Epcoritamab
Drug: Prednisone
Drug: Rituximab
Drug: Lenalidomide
Drug: Doxorubicin
Drug: Vincristine
Drug: Bendamustine
Drug: Cyclophosphamide
Drug: Obinutuzumab

First Posted Date: 2024-01-05

Last Posted Date: 2025-04-30

Lead Sponsor: Genmab

Target Recruit Count: 1095

Registration Number: NCT06191744

Locations: 🇫🇷
Hôpital Saint-Louis /ID# 260509, Paris, France
🇫🇷
Clinique Sainte-Anne /ID# 261528, Strasbourg, France
🇨🇳
Zhujiang Hospital of Southern Medical University /ID# 260558, Guangzhou, Guangdong, China

and more 217 locations

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Phase 1

Recruiting

Conditions: Recurrent Chronic Lymphocytic Leukemia
Recurrent Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Marginal Zone Lymphoma
Recurrent Transformed Chronic Lymphocytic Leukemia
Refractory Mantle Cell Lymphoma
Refractory Transformed Chronic Lymphocytic Leukemia
B-Cell Non-Hodgkin Lymphoma
Recurrent Small Lymphocytic Lymphoma
Refractory Diffuse Large B-Cell Lymphoma

Interventions: Biological: Autologous BAFFR-targeting CAR T Cells
Drug: Bendamustine
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Computed Tomography
Drug: Cyclophosphamide
Procedure: Echocardiography
Drug: Fludarabine
Procedure: Leukapheresis
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2024-01-05

Last Posted Date: 2024-07-16

Lead Sponsor: Mayo Clinic

Target Recruit Count: 27

Registration Number: NCT06191887

Locations: 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Phase 3

Recruiting

Conditions: Hodgkin Lymphoma

Interventions: Biological: JS004 in combination with Toripalimab
Drug: Bendamustine or gemcitabine

First Posted Date: 2023-12-14

Last Posted Date: 2025-02-28

Lead Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Target Recruit Count: 185

Registration Number: NCT06170489

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Phase 1

Withdrawn

Conditions: Prostate Carcinoma
Stage III Prostate Cancer AJCC v8
Stage IV Prostate Cancer AJCC v8
Prostate Small Cell Neuroendocrine Carcinoma

Interventions: Drug: Bendamustine
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Bridge Therapy
Procedure: Computed Tomography
Drug: Cyclophosphamide
Procedure: Echocardiography
Drug: Fludarabine
Procedure: Leukapheresis
Procedure: Multigated Acquisition Scan
Biological: T-cell Receptor-engineered T-cells
Procedure: X-Ray Imaging

First Posted Date: 2023-10-23

Last Posted Date: 2025-04-01

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT06094842

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma

Phase 3

Recruiting

Conditions: Follicular Lymphoma (FL)

Interventions: Drug: Odronextamab
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone/prednisolone
Drug: Bendamustine

First Posted Date: 2023-10-19

Last Posted Date: 2025-05-20

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 478

Registration Number: NCT06091254

Locations: 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
HOPE Cancer Center of East Texas, Tyler, Texas, United States
🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States

and more 168 locations

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Phase 3

Recruiting

Conditions: Lymphoma

Interventions: Drug: Rituximab
Drug: Obinutuzumab
Drug: Glofitamab
Drug: Bendamustine
Drug: Tocilizumab
Drug: Lenalidomide

First Posted Date: 2023-10-16

Last Posted Date: 2025-05-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 182

Registration Number: NCT06084936

Locations: 🇫🇷
CHU NANTES - Hôtel Dieu, Nantes, France
🇧🇷
ICTR Curitiba, Curitiba, Paraná, Brazil
🇨🇳
Chongqing Cancer Hospital, Chongqing, China

and more 71 locations

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations

Phase 1

Active, not recruiting

Conditions: Metastatic Malignant Solid Neoplasm

Interventions: Drug: Bendamustine
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Cyclophosphamide
Procedure: Echocardiography
Drug: Fludarabine
Procedure: Leukapheresis
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan
Procedure: Positron Emission Tomography
Biological: T-cell Receptor-engineered T-cells